The United States Food and Drug Administration has approved use of the combination of BRAF and MEK inhibitors for BRAF V600E mutant malignant melanomas, anaplastic thyroid cancers, non-small cell lung cancers, pediatric low grade gliomas requiring systemic therapy and metastatic unresectable solid tumors as a tissue agnostic treatment. Here, MAP2K7 is linked to central nervous system cancer.